Geode Capital Management LLC Trims Stock Holdings in Haemonetics Corporation $HAE

Posted by George Bondi on Jun 7th, 2026

Geode Capital Management LLC trimmed its holdings in Haemonetics Corporation (NYSE:HAE – Free Report) by 0.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,194,551 shares of the medical instruments supplier’s stock after selling 8,829 shares during the period. Geode Capital Management LLC owned approximately 2.57% of Haemonetics worth $95,758,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of HAE. AQR Capital Management LLC grew its stake in Haemonetics by 372.8% in the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after buying an additional 1,678,630 shares in the last quarter. Millennium Management LLC increased its holdings in Haemonetics by 4,296.3% during the 3rd quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock worth $37,685,000 after acquiring an additional 755,592 shares during the period. Invenomic Capital Management LP increased its holdings in Haemonetics by 1,691.5% during the 3rd quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock worth $24,288,000 after acquiring an additional 470,502 shares during the period. Balyasny Asset Management L.P. bought a new position in Haemonetics in the 3rd quarter valued at $15,703,000. Finally, Qube Research & Technologies Ltd bought a new position in Haemonetics in the 3rd quarter valued at $13,178,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Stock Up 2.1%

Shares of NYSE:HAE opened at $71.31 on Friday. The firm has a fifty day moving average price of $60.00 and a two-hundred day moving average price of $67.27. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The company has a market cap of $3.24 billion, a price-to-earnings ratio of 35.30, a PEG ratio of 1.43 and a beta of 0.56. Haemonetics Corporation has a one year low of $47.31 and a one year high of $87.32.

Haemonetics (NYSE:HAE – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.01. The firm had revenue of $346.35 million for the quarter, compared to analysts’ expectations of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the company posted $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Analysts anticipate that Haemonetics Corporation will post 5.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HAE has been the subject of several analyst reports. Weiss Ratings downgraded shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, May 21st. Mizuho cut their price target on shares of Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Monday, April 13th. JPMorgan Chase & Co. cut their price target on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Barrington Research cut their price target on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a report on Tuesday, May 12th. Finally, Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $77.11.

Get Our Latest Analysis on Haemonetics

Haemonetics Company Profile

(Free Report)

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

Geode Capital Management LLC Trims Stock Holdings in Haemonetics Corporation $HAE

Haemonetics Stock Up 2.1%

Analyst Upgrades and Downgrades

Haemonetics Company Profile

See Also

You might be interested in: